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MitochondriaAlthough Alzheimer's disease (AD) is themost commonneurodegenerative disease, the etiology of AD is not well
understood. In some cases, genetic factors explain AD risk, but a high percentage of late-onset AD is unexplained.
The fact that AD is associated with a number of physical and systemic manifestations suggests that AD is a mul-
tifactorial disease that affects both the CNS and periphery. Interestingly, a common feature ofmany systemic pro-
cesses linked to AD is involvement in energymetabolism. The goals of this review are to 1) explore the evidence
that peripheral processes contribute to AD risk, 2) explore ways that AD modulates whole-body changes, and
3) discuss the role of genetics, mitochondria, and vascular mechanisms as underlying factors that could mediate
both central and peripheralmanifestations of AD. Despite efforts to strictly deﬁne AD as a homogeneous CNS dis-
ease, theremay be no single etiologic pathway leading to the syndromeof AD dementia. Rather, the neurodegen-
erative process may involve some degree of baseline genetic risk that is modiﬁed by external risk factors.
Continued research into the diverse but related processes linked to AD risk is necessary for successful develop-
ment of disease-modifying therapies.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common form of dementia,
affecting nearly 10% of individuals over the age of 65 and nearly 50%
of those over the age of 85 [1]. Increasing longevity in the popula-
tion combined with the high incidence of AD in older adults will
only exacerbate the societal and economic impact of AD in coming
years. The neuropathological hallmarks of AD include amyloid
plaques and neuroﬁbrillary tangles which are present on micro-
scopic examination of the brain. These neuropathological changes
are accompanied by accelerated atrophy in the brain's gray matter
cortex, reﬂecting loss of neurons, in areas such as the hippocampus
and parietal lobes. Ultimately, both gray and white matter abnor-
malities are observed [2]. The earliest clinical features of AD include
short term memory impairment and executive dysfunction corre-
sponding to neurodegeneration in areas that mediate these func-
tions [3].
AD is classically viewed as a primary neurodegenerative process.
In its terminal phases, however, it is well-known that AD patients
have physical decline and thus the AD process quite clearly is associ-
ated with systemic manifestations that extend beyond the CNS. This
physical decline is undoubtedly driven to some extent by theol of Medicine, Department of
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R.H. Swerdlow),progressive functional and behavioral decline associated with the
CNS degeneration [4]. On the other hand, physical decline is observ-
able to varying degrees in the earliest stages of the disease, prior to
the presence of signiﬁcant functional and behavioral decline that
clearly underlies some of the physical manifestations seen late in
the disease [5].
The presence of physical or systemic manifestations of AD early in
the disease, or even before the onset of clinically recognizable symp-
toms, suggests that physical declinemay not simply represent a second-
ary result of the CNS pathological process. In fact, studies have long
suggested that abnormalities in metabolic and biochemical processes
described in AD brains are also present in peripheral cells such as skin
ﬁbroblasts derived from AD patients [6,7]. Individuals with AD also
have mitochondrial dysfunction evident in both the CNS and periphery
[8] (for example, lymphocytes [9]) suggesting that pathological pro-
cessesmay co-exist in both brain and non-neural tissues. There remains
uncertainty regarding the causal relationship between these variables.
To what extent the systemic changes represent an effect of a CNS pro-
cess, contribute causally to the CNS disease, (i.e., reverse causation) or
reﬂect a biological process that is present in both body and brain re-
mains unclear.
This review sets out to examine these systemic manifestations
of AD through the lens of three hypotheses asserting different
cause and effect relationships: 1) systemic processes drive CNS
dysfunction (for instance, as risk factors for brain dysfunction
and AD), 2) AD brain processes drive systemic manifestations
(i.e., downstream effects), and 3) a common underlying biological
process is present both peripherally and in the CNS suggesting a
systemic etiological process. We will also review the concept that
Fig. 1.Potential risk factors for AD.Wepropose that a combination of nuclear andmitochondrially-encoded genes determine one's baseline risk for AD. This baseline risk can bemodiﬁed—
either increased (+) or decreased (−) by a wide variety of environmental factors, (diet, exercise) socioeconomic factors (i.e. education) and inevitably by the aging process.
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systemic processes.
2. Alzheimer's disease and whole body changes: the chicken or
the egg?
Association studies clearly demonstrate that patients with AD have a
number of systemic (i.e., non-CNS) manifestations that accompany the
CNS dysfunction that deﬁnes AD. Risk factor studies suggest that the
neurodegenerative process may be instigated or exacerbated to some
degree by peripheral processes. On the other hand, some of the periph-
eralmanifestationsmay be the downstream result of AD processes, me-
diated by dysfunctional CNS control of peripheral processes or through
behavior changes (i.e., reduced physical activity, forgetting to eat) that
result in systemic manifestations. The primary goal of this review is to
summarize evidence in favor of these possibilities and examine a third
possibility that a systemic underlying factor may be common to both
CNS and peripheral dysfunction associated with the clinical AD
syndrome.2.1. Systemic processes contribute to AD
A large number of apparent risk and protective factors have been
identiﬁed that appear to inﬂuence an individual's long term risk of devel-
oping AD. Some risk components are likely genetic in nature, although
additional factors likely involve processes that originate outside of the
CNS, such as diabetes, obesity, and physical inactivity. The precisemech-
anisms of their inﬂuence on AD risk likely include broad systemic effects
that presumably transfer to the brain and either inﬂuence the initiation
of disease processes or exacerbate the CNS dysfunction underlying the
disease. Here, we review evidence that systemic factors may contribute
to the initiation or exacerbation of AD.2.1.1. Physical activity
Physical exercise results in broad physiologic adaptations including
improvements in cardiovascular ﬁtness, vascular health, metabolic pro-
ﬁle (reduced body fat, increased insulin sensitivity) and body composi-
tion (increased lean mass and bone density) [10]. Increasing evidence
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tively impacts brain health through a number of potential mechanisms.
Increasedphysical activity decreases AD risk [11] and has beenpostulat-
ed to have a trophic effect on the brain, particularly the hippocampus.
For instance, exercise is associated with increased brain-derived neuro-
trophic factor (BDNF) [12] and other important neurochemicals [13],
supporting a role of exercise in brain growth and survival. Exercise ap-
pears to stimulate neurogenesis [14] as evidenced by increased counts
of new neurons in adult animals on an exercise regimen. Broadly, exer-
cise may modulate vascular risk factors (atherosclerosis [15], heart dis-
ease [16], stroke [17], diabetes [18–23]) that place an individual at risk
for dementia, vascular dementia, and AD. More speciﬁcally, studies
have shown increased inﬂammation in AD [24], and exercise decreases
systemic inﬂammatory markers [25].
Numerous clinical studies suggest a relationship between physical
activity and risk of dementia in late life. Cross-sectional studies suggest
that physical activity is positively associatedwith cognition, particularly
executive and visuospatial function [26–30].Multiple longitudinal stud-
ies report a relationship between self-reported exercise and cognitive
decline [31–36], and overall physical activity inmidlife or later life is as-
sociated with a reduced risk of developing AD in late-life [37,38]. These
longitudinal studies suggest that systemic beneﬁts of physical activity
may modulate positive cognitive outcomes. This line of thought is fur-
ther supported by results from intervention studies that have shown
improvements in cognitive outcomes following exercise [39–43]. We
and others have shown that physical activity and ﬁtness levels are asso-
ciated with larger brain volume [42,44,45]. This relationship may be
mediated by exercise effects on neurotrophic factors such as BDNF.
Serum levels of BDNF are positively correlated with hippocampal vol-
ume [46] and exercise acutely increases hippocampal levels of BDNF
in animals [47] while blocking BDNF function ameliorates exercise-
induced improvement in cognitive function [48].
Most of the data supporting a link between exercise and brain health
comes from studies of aerobic exercise – walking is the most common
form of physical activity for older adults – and little data exists on the
role of resistance exercise (i.e., weight lifting) in promoting brain health.
There is evidence that resistance exercise may be important in
preventing age- and AD-related cognitive decline. For instance, several
small studies have found that resistance training is associated with
modest cognitive beneﬁts in those with [49] and without cognitive im-
pairment [43]. Association studies suggest that reducedmuscle strength
is a risk factor for developing AD [50] and that lower strength is associ-
ated with greater cognitive decline [51]. These association studies how-
ever, cannot assess the cause and effect relationship of muscle strength
with cognitive decline and it remains unclear if the declines in muscle
strength causally inﬂuence AD processes or are a consequence of the
early disease process. In fact, AD is associated with measurable changes
in body composition, including lean mass and bone density [52–54],
suggesting that body composition changes are an early systemic mani-
festation of AD rather than factors that exacerbate or initiate the disease
process. This will be reviewed inmore detail below. Nevertheless, there
is strong evidence that the physiologic adaptations (increased cardiore-
spiratory ﬁtness, metabolic proﬁle, increased muscle mass) from exer-
cise and physical activity may result in beneﬁcial brain effects that
result in a lower risk of AD and dementia.
2.1.2. Type 2 diabetes
Another peripheral process linked to risk and progression of AD is
impaired glucose metabolism. Numerous epidemiologic studies have
shown that diabetes and insulin resistance are strong risk factors for
cognitive decline and AD [55–60], and we and others have shown that
impaired glucose metabolism is associated with increased progression
from mild cognitive impairment to AD [61,62]. Moreover, clinical stud-
ies using FDG-PET have demonstrated that decreased glucose metabo-
lism occurs very early in AD brain and is predictive of disease
diagnosis [63,64].Several potential mechanisms may link insulin resistance and brain
function. Insulin can cross the blood brain barrier [65], where it likely
modulates several processes including neurotransmission [66–68] cell
survival [69], and amyloid trafﬁcking [70]. Insulin signaling deﬁcits are
present in AD brain post-mortem [71,72], although the temporal rela-
tionship between peripheral insulin resistance and CNS insulin resis-
tance is uncertain. Elevated peripheral insulin, which precedes and
often accompanies diabetes, is associated with an increased risk for de-
mentia [73], although high insulin levels may actually be protective in
AD by compensating for impaired insulin signaling, known to occur in
cognitively-impaired individuals [74,75]. Finally, increased glycated he-
moglobin (HbA1c), impaired fasting glucose, impaired glucose tolerance,
and homeostatic model assessment of insulin resistance (HOMA-IR)
have all been associatedwith impairedmemory performance or longitu-
dinal cognitive decline in nondemented adults [76–79].
Although it iswell-accepted that diabetes increases AD risk, the rela-
tionship between insulin resistance and amyloid pathology is some-
what more controversial. As mentioned, insulin can increase amyloid
efﬂux from the cell [70], and insulin and amyloid compete for receptor
binding and are even degraded by a common enzyme [80,81]. However,
using advanced imaging techniques, one very recent study has indicat-
ed no relationship between insulin resistance and amyloid during life
[82], and supports previous work that showed diabetic individuals did
not have more brain amyloid at autopsy compared to controls [55]. It
is thus possible that individuals with metabolic impairment are simply
more vulnerable to the effects of amyloid aggregation than healthy indi-
viduals, or perhaps that aggregation of a protein other than amyloid-
beta affects these individuals. In fact, autopsy data indicate that amylin,
a peptide produced in the pancreas and co-secretedwith insulin, aggre-
gates in the brain of individuals with both AD and vascular dementia in-
dependent of amyloid-beta deposition [83]. It has also been shown in
animal models that the receptor for amylin may modulate amyloid-
beta's effects on long-term potentiation [84]. However, further studies
are needed to determine whether amylin plays a role in cognitive de-
cline and AD.
2.1.3. Obesity and lipid metabolism
Obesity is an important risk factor for dementia and AD. The rela-
tionship between obesity and dementia risk seems to peak at mid-life
[85,86] and in ameta-analysis was shown to occur independently of di-
abetes diagnosis [87]. Higher BMI inmidlife is associatedwith structural
brain changes [88,89] and increased risk of cognitive decline and AD in
late life [90,91]. Thus, it is possible that dysregulation of systemic meta-
bolic processes related to obesity and lipid metabolism may also affect
late life AD risk.
The relationship betweenmidlife obesity and AD riskmay bemodu-
lated indirectly through vascular mechanisms (discussed below). How-
ever, a more direct potential link between obesity and cognitive decline
involves lipids. Dyslipidemia occurs frequently in obese individuals [92],
and is characterized by increased levels of low density lipoprotein
(LDL). In culture, oxidized LDL is associated with increased formation
of “lipid rafts” [93,94], which are groups of molecules that change the
ﬂuidity of the plasmamembrane and are integral to cell signaling. Inter-
estingly, the processing of amyloid precursor protein to form amyloid-
beta depends upon dynamic interactions with these microdomains
[95]. In fact, recentwork has shown that palmitoylation of APP increases
amyloid processing through targeting of APP to lipid rafts [96].
Lipid raft formation directly affects recruitment of signaling proteins
and receptors to particular regions of the membrane. Cholesterol,
sphingomyelin, and ceramide are important components of lipid rafts,
and reduced sphingomyelin and increased ceramide levels have been
observed in AD plasma [97]. Very recently, subjects in the middle and
highest tertiles of ceramide at baseline had a 10 and 7.6-fold increased
risk of AD, respectively [98]. However, another study indicated that cer-
amide only predicted cognitive decline and neuronal loss in subjects
with MCI [99]. Thus, the effect of disease stage on the relationship
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amide has been shown to increase amyloid-beta generation [100], Apo-
lipoprotein (APOE) binding [101], and APOE secretion [102], and
sphingomyelinase (which generates ceramide) may be involved in cell
death [103,104]. Studies have also shown that ceramide can play a
role in insulin resistance and mitochondrial dysfunction (reviewed in
[105]), making this molecule an intriguing player in multiple systemic
processes that have been linked to AD.
Although a number of studies suggest that obesity is a risk factor for
dementia and AD, this risk effect appears to be modiﬁed, and perhaps
reversed, by age. Studies in older adults, rather thanmiddle aged adults,
suggest that a higher BMI may be associated with a lower risk of cogni-
tive decline, dementia, and AD [106–108]. As discussed below in more
detail, these observations suggest that obesity may inﬂuence long
term risk of AD but that the early or preclinical stages of AD may be as-
sociated with weight loss.2.1.4. Inﬂammation and cytokines
A number of studies suggest that inﬂammatory processesmay play a
role in AD. Although increasedmarkers of inﬂammation are observed in
AD brain postmortem [109], these likely reﬂect local neurodegenerative
processes occurring in the brain. Thus, studies have examined if plasma
biomarkers can predict cognitive decline and AD risk. Tumor necrosis
factor alpha (TNF-α) has been associated with cognitive decline [110],
and both TNF-α and another inﬂammatory molecule, IL-1β, have been
associatedwith increased AD risk [111]. Inﬂammatory processes are ac-
tually a common link between many AD risk factors discussed in this
section: TNF-α, for instance, has been shown to be increased in T2D
and obesity, and decreased with exercise [112], although not all studies
are consistent. Interestingly, a very recent large study that analyzed data
from 3 independent cohorts found that only 4 plasma analytes (APOE,
B-type natriuretic peptide, C-reactive protein, and pancreatic polypep-
tide) were linkedwithMCI or AD diagnosis [113]. One of these analytes,
C-reactive protein, is known to be particularly responsive to inﬂamma-
tory processes.
Although some studies have linked peripheral inﬂammatory
markers to AD, clinical trials to reduce inﬂammation have produced
contentious ﬁndings. For instance, in cross-sectional and population-
based cohort studies, use of anti-inﬂammatory drugs is associated
with reduced AD risk [114–116]. However, clinical trials have failed to
show that anti-inﬂammatory therapy prevents AD [117] or improves
cognitive function in either AD subjects or individualswith family histo-
ry of AD [118,119]. Safety concerns were often noted, and one trial was
halted [120]. In summary, although peripheral inﬂammation has been
observed in AD, the degree to which inﬂammation drives brain changes
is unclear and at the present time there is little clinical evidence that in-
ﬂammation is an efﬁcacious target for AD prevention or treatment.2.2. AD drives systemic changes
It is well known that the brain mediates a variety of peripheral pro-
cesses throughmechanisms such as the autonomic nervous system and
motor circuits. For instance, the CNSmodulates bonehealth through au-
tonomic output from the hypothalamus [121], a central regulator of a
number of peripheral metabolic processes. Additionally, as AD brain
dysfunction progresses the associated functional declines result in re-
duced levels of physical activity which may in turn result in body com-
position changes (i.e. increased fat mass and reductions in lean mass
and bone density). Thus, CNS processes can inﬂuence peripheral pro-
cesses both directly (i.e. autonomic output) or indirectly through be-
havioral and functional changes (i.e., reduced physical activity,
forgetting to eat). This section reviews evidence of peripheral effects
that may be mediated or modulated by the AD neurodegenerative
process.2.2.1. Body composition
As discussed, obesity is a clear risk factor, particularly in midlife, for
the future development of AD. However, there is substantial evidence
that changes in body composition, such as weight loss, occur in the ear-
liest or even preclinical stages of AD. These ﬁndings suggest that as early
CNS manifestations of AD occur in the brain (i.e., plaques and tangles)
there are co-occurring systemic changes associated with the onset of
disease.
As noted above, while higher body mass index (BMI) is associated
with increased dementia risk [90,91], this risk appears to attenuate or
reverse in older adults where higher BMI is associated with a lower
risk of cognitive decline, dementia, and AD [106–108]. In fact, studies
using sensitive measures of body composition suggest that changes in
leanmass (i.e. muscle mass) and bone density may be among the earli-
est manifestations of the AD clinical syndrome. We have found that in-
dividuals in the early stages of AD have reduced lean mass [52] and
lower bone density [53] than nondemented controls. Bone density has
been correlated speciﬁcally with measures of hypothalamic atrophy in
AD, while reductions in leanmass and bone density were both associat-
ed with greater whole brain atrophy and cognitive decline [54]. Reduc-
tions in leanmassmay be attributed in part to functional impairment in
individualswith AD,which can result in feedingdifﬁculties, especially in
subjectswith aged caregivers [4], although our studies included individ-
uals in the earliest stages of AD when these types of difﬁculties are not
overtly present.
Although functional impairments occurring in later stages of ADmay
contribute to the observed decrease in bodyweight, other research sug-
gests that weight loss occurs before signiﬁcant functional decline has
begun. For instance, weight loss has been shown to occur prior to devel-
opment of AD [5]. In a prospective study that followed following elderly
individuals for 20 years, individuals who were diagnosed with AD at
follow-up had lost more weight since baseline than individuals with
normal cognition. In this case, weight loss occurred prior to AD diagno-
sis, indicating that this effect was likely not due to functional or behav-
ioral changes impacting nutrition [122]. Lower BMI is associated with
faster cognitive decline over one year in individuals with MCI [106],
consistent with studies suggesting that weight loss in elderly individ-
uals may be an early systemic manifestation of the AD process
[123–127]. An inverse relationship has been observed between BMI
and AD biomarkers in both normal and cognitively-impaired subjects,
with the relationship most strongly evident in individuals with MCI
[128]. MCI is a heterogeneous pathological state, suggesting that indi-
viduals with MCI who are normal or low weight (BMI 18.5–25 kg/m2)
are more likely to have amyloid-based cognitive impairment compared
to those who are overweight (BMI N 25 kg/m2) [128].
Interestingly, a relationship between BMI and AD neuropathology
has also been observed in cognitively-normal elderly subjects. We and
others have shown that neuropathological changes of AD found at au-
topsy are associated with low and declining body mass index (BMI)
[128,129]. Given that elevated BMI at midlife is a risk factor for AD, it
is possible that lowBMI in late life is somehow a consequence of the dis-
ease process. However, this relationshipmay also suggest that there are
multiple etiologies leading to AD. For instance, it is possible that individ-
uals with elevated BMI may exhibit more vascular-related pathology
and lower amyloid neuropathology for a given level of cognitive func-
tion, while subjects with lower BMI may be more apt to exhibit more
classic AD neuropathology in the absence of vascular disease.
2.2.2. Physical function and ﬁtness
Motor slowinghas been observed in subjectswith early AD [130], in-
dicating that motor dysfunction may be a very early manifestation of
disease. Cognitively-impaired subjects have been shown to exhibit
greater decline in strength and performance on tests of physical func-
tion compared to controls [131], and it is reported that cognitive decline
predicts decline in the upper muscle strength [132]. Along these lines,
we have found that AD subjects also exhibit reduced VO2peak
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this reduction is correlatedwith brain atrophy [44,45]. Similarly, our im-
aging studies suggest that decreased aerobic ﬁtness is associated with
hippocampal atrophy in early AD [133]. It is possible that declining func-
tional capacity, especially in later stages of the disease, has a detrimental
effect on physical ﬁtness in these individuals. However, mild decreases
in VO2peak have been observed by us even in the earliest clinical stages
of the disease prior to the emergence of clinically signiﬁcant physical
function impairment. This suggests that motor dysfunction may not
simply be the result of progressive CNSdysfunction but an early system-
ic manifestation of the disease.
2.3. Common peripheral and CNS etiological processes
Data from the prior sections suggests that systemic processes can
inﬂuence AD risk while AD-related CNS dysfunction can inﬂuence
whole-body health. In this section, we will review evidence suggesting
that abnormal physiologic processes may underlie both whole body
and brain health. For instance, mitochondrial dysfunction is one under-
lying factor that precedes both CNS neuropathological manifestations
and peripheral metabolic dysfunction often observed in AD. Thus, a
common underlying etiological process may mediate some of the ap-
parent co-occurring decline in both the body and the brain that is asso-
ciated with the clinical syndrome of AD.
2.3.1. Genetic factors
Genetic factors are likely to play a common underlying role in pe-
ripheral and central dysfunction associated with AD, although the func-
tional actions of many of the risk genes for AD are not fully known. The
most commonly identiﬁed gene that increases sporadic AD risk in
roughly 40% of individuals is Apolipoprotein ε4 (APOE ε4). APOE is in-
volved in lipid transport and cholesterol metabolism within the cell
[134]. Interestingly, differences in regional white and gray matter are
detectable in APOE ε4 carriers from infancy [135]. Although the precise
mechanisms are still notwell understood, we have previously discussed
evidence that aberrant lipid metabolism may play a role in AD risk. We
and others have found that the APOE ε4 allele is associated with de-
creased cognition, graymatter volume inmemory areas (the hippocam-
pus), white matter tract integrity, and increased magnetic resonance
imaging markers for cardiovascular disease [136–138]. Furthermore,
decreases in cerebral glucose metabolism are a known biomarker for
AD [139], and cognitively-normal, middle-aged APOE ε4 carriers have
AD-like changes in cerebral glucosemetabolism [140,141], with a possi-
ble gene-dose effect [142].
A handful of studies using functional magnetic resonance imaging of
the default mode network (DMN) have also shown differential oxygen
uptake in the brain at rest in young APOE ε4 carriers, indicating differ-
ences in brain metabolic function early in life [143–145]. Some have ar-
gued that default mode network changes may more closely represent
actual brain oxygen consumption [146,147] and thus mitochondrial
function. In fact, cytochrome oxidase activity, amarker ofmitochondrial
bioenergetics, has been measured directly in the brains of young adult
APOE ε4 carriers. These individuals exhibited mitochondrial dysfunc-
tion decades before they would likely have any cognitive symptoms
[148]. This indicates a potential underlying factor for the effects of geno-
type and mitochondrial bioenergetics, which will be discussed later.
Moreover, genetics may even affect the responsiveness of individuals
to interventions that aim to reduce AD risk: the ﬁnding that higher
leisure-time physical activity decreased AD risk in late lifewas strongest
in individuals whowere APOE ε4-positive [149]. However, recent stud-
ies that have examined insulin resistance in APOE ε4 carriers have not
shown any effect of genotype [150,151], suggesting that the relation-
ship between insulin resistance and AD may be through a separate
mechanism.
Although APOE ε4 is by far the most widely-recognized genetic risk
factor of late-onset AD, other genes have also been linked to AD. To date,660 candidate genes for AD risk have been identiﬁed, although results
are inconsistent between studies. The development of genome-wide as-
sociation studies (GWAS) has greatly improved AD genetic knowledge
[152]. GWASwith fewer than 1000 cases or control subjects have impli-
cated novel AD risk single nucleotide polymorphisms (SNPs) in
GOLPH2, GAB2, and PCDH11X genes [153–156]. More powerful, higher
number case and control GWAS have identiﬁed or replicated novel AD
risk SNPs in BIN1, CLU, CR1 and PICALM genes [157–164], and a recent
meta-analysis of GWAS identiﬁed a total of 20 genetic susceptibility
loci (11 new genes, in addition to 9 previously-identiﬁed risk genes)
[156]. However, interpretation of GWAS ﬁndings to reveal disease-
relevant biologicalmechanisms remains a challenge because the genetic
architecture of AD is incomplete [165]. Even themost robust genetic as-
sociations appear to explain only a small portion of the disease burden
in the population, with the majority of the heritable component of the
disease unexplained.
2.3.2. Mitochondrial dysfunction
There is a large body of evidence that mitochondrial dysfunction,
and perhaps energy failure, plays a central role in AD pathophysiology
[166,167]. Mitochondrial deﬁcits in AD are not isolated to neurons, but
occur systemically [8,168]. Mitochondrial dysfunction likely contributes
to insulin resistance [169] and has been shown to occur in pre-diabetic
animal models [170]. Very recently, mitochondrial dysfunction at the
molecular level was shown to lie upstream of pancreatic beta-cell
death and was linked to development of diabetes in mice [171]. More-
over, muscle contraction, as occurs during exercise, has been linked to
improvement in mitochondrial energy metabolism and to normaliza-
tion of insulin signaling [172]. It is possible that mitochondrial dysfunc-
tion is one underlying factor that precedes both CNS neuropathological
symptoms and contributes to peripheral metabolic dysfunction often
observed in AD.
Family history studies also support a role for mitochondrial dysfunc-
tion in AD. In contrast to nuclear DNA, mitochondrial DNA is inherited
maternally, and both speciﬁc mitochondrial haplotypes and maternal
family history are linked to AD-related structural, cognitive, CSF, and
metabolic biomarkers [173–176]. These ﬁndings of increased AD-
related change in maternal lines of AD suggest that transmission of
risk is preferentially found in maternal inheritance. This provides indi-
rect evidence that mitochondrial function is related to manifestation
of AD symptoms. Perhaps more intriguing than genetic risk, however,
is that mitochondrial dysfunction accumulates throughout the aging
process [177–179]. This suggests a role for both inherited and acquired
mitochondrial dysfunction in modulating AD risk. In AD patients, overt
markers of mitochondrial dysfunction have been consistently observed.
For instance, activity of cytochrome c oxidase, an enzyme in the electron
transport chain essential for energy production, is decreased in the
brains of AD patients [168,180–184] and in adult childrenwith amater-
nal family history of AD [185]. Furthermore,mitochondrial DNA isolated
from AD brain exhibits a loss of integrity, such as increased number of
deletions and mutations [186–188].
Interestingly, alterations in the association of mitochondria with
other cellular compartments are also observed in AD and may further
contribute to mitochondrial dysfunction. For instance, mitochondria
are normally associated with the endoplasmic reticulum (ER) through
physical ER connections called mitochondria associated membranes
(MAMs). These structures play an important role in communication be-
tween themitochondria and ER, linking them structurally and function-
ally. These membrane areas have the characteristics of previously
discussed lipid rafts, and the activity of enzymes linked to AD, such as
γ-secretase, is heavily enriched in MAM regions [189,190]. MAMs are
important for regulating processes such as phospholipid synthesis and
calcium levels [191,192] andmay provide a potential link between pro-
cesses such as apoptosis and synchronization of energy production and
energy use via calcium signaling [189,192,193]. The function ofMAMs is
altered in AD, with consequences ranging from mitochondrial
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regulated calcium homeostasis, and a failure to adequately match ener-
gy supply and demand due to downregulation of key enzymes may all
contribute to mitochondrial damage. This evidence provides an addi-
tional potential link between mitochondrial function, lipid metabolism,
and AD.
It is known that overproduction of reactive oxygen species (ROS)
and subsequent oxidative stress plays a key role in mitochondrial dys-
function [195]. Interestingly, mitochondria themselves are the primary
source of ROS production in the cell [196]. Under normal conditions,
ROS serve important signaling functions [197], but damaged mitochon-
dria can overproduce ROS and increase cellular oxidative stress [196].
ROS generation is increased inMCI [198], and oxidative stress canmedi-
ate AD pathophysiology through increased production and secretion of
amyloid beta (Aβ) [199,200]. In fact, mitochondrial dysfunction may
play a role in the downstream protein aggregation that serves as the
neuropathological hallmark of AD. Aβ deposition initially occurs within
the neuron [201], and Aβ trafﬁcking into mitochondria precedes plaque
formation [202]. Cell culture studies have shown that functional mito-
chondria are necessary for Aβ to induce cellular toxicity [203]. Although
the temporal relationship between impaired mitochondrial function
and amyloid neuropathology in humans is not well understood, studies
in transgenic mice suggest that mitochondrial dysfunction occurs prior
to Aβ plaque formation [204]. Furthermore, Aβ is postulated to impair
mitochondrial protein import [205], and complex IV dysregulation in
triple transgenic AD mice is dependent on Aβ [206], providing multiple
mechanisms for impaired mitochondrial function. These effects may
trigger a vicious cycle where damaged mitochondria can generate Aβ
and Aβ can then enter mitochondria and exacerbate damage. Interest-
ingly, amyloid is imported into mitochondria by translocase of the
outermembrane (TOM)machinery [207], and TOMM40,which encodes
the channel protein subunit of the translocase of the outermitochondri-
al membrane (TOMM) complex [208] is in high linkage disequilibrium
with APOE [209]. This makes it difﬁcult to discern which gene actually
contributes to AD risk.
2.3.3. Vascular mechanisms
The strongest modiﬁable risk factors for AD are also risk factors for
vascular disease, including sedentary behavior, glucose intolerance,
and obesity [210,211]. Vascular pathologies are increasingly recognized
as having an important role in late-life dementias given recent observa-
tions of the heterogeneity of associated dementia pathologies [212]. Al-
thoughmost studies attempt to describe vascular and ADpathologies as
discrete syndromes, the clinical and neuropathological boundaries fre-
quently overlap. Vascular-related injury often coexists with AD neuro-
pathology at autopsy [213], and the presence of cerebrovascular
disease lowers the burden of AD neuropathological changes associated
with a given level of cognitive impairment [214,215]. Many individuals
clinically diagnosed with AD actually exhibit a “mixed dementia” with
both AD neuropathological changes and abnormalities indicative of vas-
cular damage [216,217].
Mechanistically, vascular mechanisms may compromise cognitive
function and contribute to AD in several ways. For instance, cardiovas-
cular risk factors are linked to white matter lesions in elderly subjects
[218]. White matter lesions are prevalent in both aging and AD [215],
andwe have shown that cardiorespiratory ﬁtness correlates with longi-
tudinal brain atrophy inAD [133]. Moreover,many conditions comorbid
with vascular disease, such as hypertension and diabetes, have been
linked to dementia. High blood pressure has been observed in subjects
with both AD and vascular dementia [219], and high blood pressure
during midlife is associated with increased late life AD risk [220]. The
link between AD anddiabetes has been previously discussed, but it is in-
teresting that pancreatic dysfunction is linked to high levels of amylin,
which aggregates in a manner similar to amyloid-beta and causes pan-
creatic beta-cell cytotoxicity [221]. Amylin also aggregates in the brain
in both vascular dementia and AD, linking peripheral metabolicdysfunction with vascular disease and cognitive decline [83]. Both AD
and vascular dementia have also been linked to decreased regional
blood ﬂow [222]. Decreased blood ﬂow to the brain reduces the critical
supply of glucose and oxygen to the brain that is necessary to sustain
proper neuronal metabolism. Finally, vascular disease may be linked
to impaired energy metabolism throughmitochondrial function. In car-
diac microvascular endothelial cells, high glucose induces apoptosis
through induction of FoxO3a [223], a transcription factor known to reg-
ulate mitochondrial gene expression and production of reactive oxygen
species [224]. A similar mechanism may also hold true for brain endo-
thelial cells.
Thus, theremay bemultiple paths to AD dementia, with genetic, mi-
tochondrial, and vascular inﬂuences. It is intriguing that diabetics, for in-
stance, have a higher risk for AD diagnosis and yet lower amyloid
pathology postmortem [216]. There is thus evidence that vascular risk
factors may lower the threshold for additional damage necessary to
cause clinical expression of AD symptoms.
3. Additional considerations
Despite efforts to strictly deﬁne AD as a homogeneous CNS disease,
there may be no single etiologic pathway leading to the syndrome of
AD dementia. An individual's baseline risk is likely determined by
inherited nuclear and mitochondrially-encoded genes. Environmental
factors, such as midlife obesity, insulin resistance, and inﬂammatory
processes, likely modify this baseline risk (Fig. 1). The contributions of
genetic vs. environmental factors certainly vary from individual to indi-
vidual in complex ways. Because environmental “risk modiﬁers” often
interact (for instance, midlife obesity can lead to insulin resistance), en-
vironmental factors may play a more central role in the development of
dementia in some individuals. These individuals may have lower levels
of traditional AD neuropathological burden (i.e. amyloid plaques and
neuroﬁbrillary tangles) compared to genetically predisposed individ-
uals who generally have higher levels of AD neuropathology. Vascular
mechanisms and processes inﬂuencing cellular stress may inﬂuence
the emergence and progression of the clinical manifestation of the de-
mentia syndrome. Continued research into the diverse but related pro-
cesses linked to AD risk is necessary, as individuals with genetic risk
(and potentially more amyloid pathology) may beneﬁt more from am-
yloid clearance drugs, whereas individuals who exhibit more vascular-
related pathologymaypreferentially beneﬁt from lifestyle interventions
such as diet and exercise.
3.1. Limitations and forward progress
Although promising, there are limitations to many studies discussed
in this article. Studies that are observational or cross-sectional, for in-
stance, cannot be used to establish causality — this requires well-
designed clinical trials. Because AD has a notably long asymptomatic
time course, and many of the classical outcome measures (such as
neuropsychometric tests) are not sensitive to the earliest signs of the
disease, design of randomized clinical trials can be difﬁcult and expen-
sive. However, there has also been exciting progress in the ﬁeld, notably
in the development of advanced imaging techniques. These techniques
can be used to determine individuals at risk for ADprior to cognitive im-
pairment. For instance, ligands that can be used to visualize both Aβ and
Tau using PET imaging in vivo will allow future randomized clinical tri-
als to investigate lifestyle interventions, such as exercise, or pharmaceu-
tical interventions that may affect brain metabolism, such as intranasal
insulin, as potential modiﬁers of AD neuropathology in the preclinical
stages of the disease.
4. Conclusions
Here we present evidence that 1) peripheral processes contribute to
AD risk, 2) AD inﬂuences whole-body changes, and 3) common
1346 J.K. Morris et al. / Biochimica et Biophysica Acta 1842 (2014) 1340–1349processes may modulate both peripheral and CNS manifestations of AD
dementia. It is our view that AD is a multifactorial disease that affects
both CNS and systemic processes. It is possible that there is no single
“smoking gun” that will explain the etiology of AD, but that several in-
terconnected processes, many of which are directly related to energy
metabolism, together determine the cognitive trajectory of individuals
that are initially at more or less risk from genetic factors.
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